Cargando…
The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side effects rema...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604799/ https://www.ncbi.nlm.nih.gov/pubmed/34841223 http://dx.doi.org/10.1016/j.isci.2021.103479 |